Reaction
Loss Of Therapeutic Response reporting signals
As of the last recalculation, Loss Of Therapeutic Response appears in 2,983 FAERS reports alongside 39 co-occurring drug terms. The strongest observed disproportionality signal is VEDOLIZUMAB (PRR 125.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Vedolizumab | 1,023 | 125.6 | 127.1 |
| Adalimumab-Aaty | 223 | 35.5 | 35.6 |
| Mesalamine | 261 | 35.4 | 35.6 |
| Infliximab-Dyyb | 126 | 31.4 | 31.5 |
| Adalimumab-Fkjp | 184 | 29.5 | 29.6 |
| Adalimumab-Adaz | 193 | 27.2 | 27.3 |
| Imatinib | 48 | 19.3 | 19.3 |
| Tofacitinib Citrate | 28 | 15.0 | 15.1 |
| Abatacept | 272 | 15.0 | 15.0 |
| Nilotinib | 49 | 11.8 | 11.8 |
| Diroximel Fumarate | 19 | 11.2 | 11.2 |
| Infliximab | 294 | 10.3 | 10.3 |
| Azathioprine | 116 | 9.5 | 9.5 |
| Ozanimod Hydrochloride | 11 | 9.3 | 9.3 |
| Romiplostim | 19 | 8.9 | 8.9 |
| Bosutinib | 11 | 8.6 | 8.6 |
| Ustekinumab | 116 | 8.2 | 8.2 |
| Budesonide | 64 | 7.7 | 7.7 |
| Dasatinib | 35 | 6.6 | 6.6 |
| Mercaptopurine | 16 | 6.5 | 6.5 |
| Suvorexant | 11 | 5.9 | 5.9 |
| Baricitinib | 8 | 5.8 | 5.8 |
| Iron | 53 | 5.6 | 5.6 |
| Canakinumab | 6 | 3.9 | 3.9 |
| Peginterferon Beta-1A | 7 | 3.7 | 3.7 |
| Busulfan | 8 | 3.6 | 3.6 |
| Dexlansoprazole | 19 | 3.2 | 3.2 |
| Upadacitinib | 36 | 3.1 | 3.1 |
| Ixekizumab | 15 | 2.8 | 2.8 |
| Golimumab | 33 | 2.7 | 2.7 |
| Abiraterone | 5 | 2.6 | 2.6 |
| Abemaciclib | 7 | 2.4 | 2.4 |
| Dimethyl Fumarate | 42 | 2.4 | 2.4 |
| Cariprazine | 3 | 2.3 | 2.3 |
| Sarilumab | 6 | 1.6 | 1.6 |
| Esketamine Hydrochloride | 4 | 1.6 | 1.6 |
| Guselkumab | 6 | 1.2 | 1.2 |
| Dupilumab | 61 | 0.9 | 0.9 |
| Apremilast | 18 | 0.9 | 0.9 |